Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectious diseases, and various forms of cancer. A central asset in their pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, and is also being investigated for COVID-19. The same compound is in Phase IIa trials for rheumatoid arthritis, having previously completed a Phase IIa study demonstrating viral remission in individuals with HIV. Additionally, Abivax is advancing ABX 196, an immune-enhancing candidate, through Phase 1/2 clinical trials for the treatment of hepatocellular carcinoma. The company also pursues research programs focused on developing therapies for Dengue fever, influenza, and respiratory syncytial virus. Incorporated in 2013, ABIVAX maintains license agreements with prominent academic and research institutions including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
